Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 5;7(1):22.
doi: 10.1186/s41181-022-00176-x.

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [18F]SiTATE PET

Carmen Wängler  1 , Leonie Beyer  2 , Peter Bartenstein  2 , Björn Wängler  3 , Ralf Schirrmacher  4 , Simon Lindner  2
Affiliations

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [18F]SiTATE PET

Carmen Wängler et al. EJNMMI Radiopharm Chem. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

None of the authors listed above declares to have any conflict of interests.

Figures

Fig. 1
Fig. 1
Maximum intensity projection (MIP) of [68Ga]Ga-DOTA-TOC (a) and [18F]SiTATE (b) PET of a 64-year-old male patient with Ileum NET (G1). The patient received Sandostatin LAR therapy between both PET scans (377 days between first and second scan), but the disease was considered stable. Blue arrows indicate comparably increased uptake of [18F]SiTATE compared to [68Ga]Ga-DOTA-TOC or vice versa. Green arrows indicate some of the lesions, which were detected in the [18F]SiTATE PET, but not in the [68Ga]Ga-DOTA-TOC PET
Fig. 2
Fig. 2
Competition experiments using [125I]I-(Leu8, d-Trp22, Tyr25)-somatostatin 28 as radioligand with increasing concentrations of SiTATE on human sst1-5 membrane preparations
See this image and copyright information in PMC

References

    1. Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1–sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38:1224–1236. doi: 10.1007/s00259-011-1760-x. - DOI - PubMed
    1. Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A. Somatostatinrezeptor PET/CT. Nuklearmedizin. 2018;57:4–17. doi: 10.1055/s-0038-1636560. - DOI - PubMed
    1. Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47:870–880. doi: 10.1007/s00259-019-04501-6. - DOI - PubMed
    1. Lindner S, Simmet M, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, Bartenstein P, Schirrmacher R, Ilhan H. Automated production of [18F]SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors. Nucl Med Biol. 2020;88–89:86–95. doi: 10.1016/j.nucmedbio.2020.07.008. - DOI - PubMed
    1. Lindner S, Wängler C, Bailey JJ, Jurkschat K, Bartenstein P, Wängler B, Schirrmacher R. Radiosynthesis of [18F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography. Nat Protoc. 2020;15:3827–3843. doi: 10.1038/s41596-020-00407-y. - DOI - PubMed

LinkOut - more resources